Hubbry Logo
EhrlichiaEhrlichiaMain
Open search
Ehrlichia
Community hub
Ehrlichia
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Ehrlichia
Ehrlichia
Ehrlichia
View on Wikipedia
from Wikipedia

Ehrlichia
Ehrlichia ewingii
Scientific classification Edit this classification
Domain: Bacteria
Kingdom: Pseudomonadati
Phylum: Pseudomonadota
Class: Alphaproteobacteria
Subclass: "Rickettsidae"
Order: Rickettsiales
Family: Ehrlichiaceae
Genus: Ehrlichia
Moshkovski 1945 (Approved Lists 1980)
Species

See text

Synonyms[1]
  • Cowdria Moshkovski 1947 (Approved Lists 1980)

Ehrlichia is a genus of Rickettsiales bacteria that are transmitted to vertebrates by ticks. These bacteria cause the disease ehrlichiosis, which is considered zoonotic, because the main reservoirs for the disease are animals.

Ehrlichia species are obligately intracellular pathogens and are transported between cells through the host cell filopodia during initial stages of infection, whereas in the final stages of infection, the pathogen ruptures the host cell membrane.[2]

History

[edit]

The genus Ehrlichia is named after German microbiologist Paul Ehrlich. The first ehrlichial disease was recognized in South Africa during the 19th century. Its tick-borne nature was determined in 1900. The organism itself was demonstrated in 1925 when it was recognized to be a Rickettsia. It was initially named Rickettsia ruminantium, and is currently named Ehrlichia ruminantium. In 1945, an "infection and treatment" method for livestock was developed. This is still the only commercially available "vaccine" against the disease, which is not a true vaccine, but intentional exposure to the disease with monitoring and antibiotic treatment if needed. In 1985, the organism was first propagated reliably in tissue culture. A new species of Ehrlichia was discovered inside the deer tick Ixodes scapularis. This newly found organism has been isolated only from deer ticks in Wisconsin and Minnesota in the USA. The species is known as Ehrlichia Wisconsin HM543746.[citation needed]

Species

[edit]

Accepted species

[edit]

The following species have been effectively and validly published:[1]

Provisional species

[edit]

The following species have been published, but are not valid according to the Bacteriological Code:[1]

  • "Ehrlichia japonica" Lin et al. 2021
  • "Ehrlichia ovina" Moshkovski 1945
  • "Ehrlichia platys" French and Harvey 1983

Candidatus species

[edit]

The following species have been published as candidatus species:[1]

  • "Candidatus Ehrlichia corsicanum" Cicculli et al. 2020
  • "Candidatus Ehrlichia khabarensis" Rar et al. 2015
  • "Candidatus Ehrlichia occidentalis" Gofton et al. 2017
  • "Candidatus Ehrlichia ornithorhynchi" Gofton et al. 2018
  • "Candidatus Ehrlichia ovata" Lynn et al. 2019
  • "Candidatus Ehrlichia rustica" Ehounoud et al. 2016
  • "Candidatus Ehrlichia senegalensis" Dahmana et al. 2020
  • "Candidatus Ehrlichia shimanensis" Kawahara et al. 2006
  • "Candidatus Ehrlichia urmitei" Ehounoud et al. 2016
  • "Candidatus Ehrlichia walkeri" corrig. Brouqui et al. 2003

Evolution

[edit]

The Ehrlichia genome contains many different variants of genes that encode outer membrane proteins,[3] which have gone through intense modification over long periods of time.[4] The great diversity in outer membrane protein genes is thought to originate from gene duplication events, followed by the fusion and fission of resulting paralogs of the gene. These duplication, fusion, and fission events form multiple gene copies and fragments, which are able to accumulate mutations. These copies and fragments of membrane proteins can then recombine, through a process called gene conversion, resulting in a new gene variant. This has a profound effect on the fitness of an organism. The survival of Ehrlichia depends greatly on the immune response of its host. With a higher range of outer membrane proteins, the parasite can evade the immune system of the host more effectively and establish persistent infection.[5]

The most pronounced evidence of evolution in the genome size of Erhlichia is the presence of tandem repeats,[3] which vary highly among individuals and species. Over time, individuals may expand or contract parts of their genes and alleles, which adds genetic variation and may sometimes affect phenotype.[3]

Ehrlichia and its closely related genus Anaplasma show extreme diversity in the structure and content of their genomes.[6] This diversity is direct result of rare clones with extreme genomes that emerged by chance after repeated bottleneck events, and this diversity persists because of the lack of selective constraints on rapid growth inside the host tissue.[6]

Ehrlichia ruminantium

[edit]

The evolutionary changes in the outer membrane proteins have led to the emergence of new strains that can infect a larger variety of hosts. Heartwater, caused by E. ruminantium, is a prevalent tick-borne disease of livestock in Africa and the Caribbean, but also threatens the American mainland. Three strains have arisen from this species due to evolutionary change in their genomes. When sequencing their genomes, many active genomic modifications have occurred, such as high substitution rates, truncated genes, and the presence of pseudogenes and tandem repeats. When analyzing substitution rates between the three strains in 888 orthologous coding DNA sequences, three coding DNA sequences were biased towards nonsynonymous substitutions that affect phenotype. In contrast, 181 coding DNA sequences were biased towards synonymous substitutions, which do not affect phenotype. This indicates that selection pressure to maintain protein function existed, and this selection acted against the nonsynonymous mutations.[3]

Ehrlichia canis

[edit]

Ehrlichia canis is a small, obligate-intracellular, tick-transmitted, Gram-negative α-proteobacterium. This species is responsible for the globally distributed canine monocytic ehrlichiosis. E. canis also shows evolution in its complex membrane structures and immune evasion strategies. These evolutionary features are derived traits that do not show up in the previous lineages, which may indicate that these features may have contributed to a fitness advantage that kept this lineage going. Unique glycoproteins and major outer membrane proteins can be expressed variously using 25 different genes. The glycoproteins are important targets of the host immune response, attachment to the host cell, and other features in the immune response. The more outer-membrane protein genes that can be expressed, the higher the chance the organism can avoid being recognized by the host's immune system.[7]

Also, reductive evolution is present in E. canis. The genome has had a severe loss of metabolic pathway enzymes compared to its ancestors. Reductive evolution in obligate intracellular pathogens is usually the direct result of genetic drift in small populations, low recombination rates, and high mutation rates. The host metabolic pathway enzymes take control of the functions lost due to reductive evolution, and this contributes to its need for a host. Natural selection may not be the reason for small genomes.[8]

Epidemiology

[edit]

Despite there being multiple strains of ehrlichiosis, only two species, E. chaffeensis and E. ewingii, are currently known to cause the disease in humans.[9]

Amblyomma americanum ticks spread E. chaffeensis and E. ewingii bacterial infection in the Eastern and Southeastern United States, while A. phagocytophilum is spread by the Ixodes scapularis tick in the Upper Midwest; 1,518 cases of E. chaffeensis were recorded in southeastern, south-central and mid-Atlantic areas of the country in 2013. Despite the first cases of "E. ewingii" appearing in the Missouri in the year 1999, this strain was not reportable to health officials until 2008. Since 2008, there have been reported human cases of E. ewingii in Oklahoma, Arkansas and Tennessee though it is observed less frequently than E. chaffeensis.[10]

During 2008–2012, 4,613 cases of E. chaffeensis infections were reported through the National Notifiable Diseases Surveillance System (NNDSS). The incidence rate (IR) was 3.2 cases per million person-years (PYs). The hospitalization rate (HR) was 57% and the case fatality rate (CFR) was 1%. During that same time, 55 cases of E. ewingii infections were reported through NNDSS. The national IR was 0.04 cases per million PY. The HR was 77% and the case fatality rate was 0%.[11]

In Minnesota and Wisconsin, four people reported symptoms that are associated with ehrlichiosis, and upon further research, neither of these cases was found to be E. chaffeensis or E. ewingii, but instead it was revealed as a new species, similar in genetic makeup to E. muris.[12] Ixodes scapularis ticks are hypothesized to be the transmitting vector of the E. muris strain in these states.[10]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Ehrlichia

View on Grokipedia
from Grokipedia
Ehrlichia is a of obligate intracellular, in the family Anaplasmataceae, order Rickettsiales, characterized as small, pleomorphic coccobacilli that replicate within membrane-bound vacuoles in host cells such as leukocytes. These tick-borne pathogens infect humans and various mammals, causing —a group of potentially life-threatening zoonotic diseases marked by fever, , and multi-organ involvement if untreated. First identified in the early , Ehrlichia species are maintained in nature through enzootic cycles involving ticks and animal reservoirs like . The genus includes several species of clinical significance, with E. chaffeensis being the primary cause of (HME), the most severe form, targeting monocytes and macrophages. E. ewingii infects granulocytes and leads to a milder ewingii ehrlichiosis, often in immunocompromised individuals, while E. muris eauclairensis has been associated with cases in the upper Midwest . Other species, such as E. canis (primarily canine) and E. ruminantium (affecting ruminants), occasionally infect humans but are less common. Ehrlichia bacteria evade host immune responses by modulating cellular processes, including inhibition of and lysosomal fusion, allowing intracellular survival and proliferation. Transmission occurs mainly through bites from infected ticks, particularly the lone star tick (Amblyomma americanum) for E. chaffeensis and E. ewingii, and the blacklegged tick (Ixodes scapularis) for E. muris eauclairensis. Cases are most prevalent in the southeastern, south-central, and mid-Atlantic United States, with annual reports increasing from about 300 in 2000 to over 2,000 by recent years, though underdiagnosis is likely due to nonspecific symptoms. Blood transfusions and congenitally from mother to fetus represent rare non-tick transmission routes. Early diagnosis via PCR or is crucial, as can progress to severe complications like or , with mortality rates of 1-3% even with treatment. remains the first-line , effective against all human-pathogenic species, and prevention focuses on tick avoidance through repellents, protective , and environmental controls. Ongoing research emphasizes and development to mitigate the rising incidence of these emerging infections.

Biology and Characteristics

Morphology and Cellular Features

Ehrlichia are intracellular that replicate exclusively within the of host cells, such as monocytes, macrophages, and granulocytes, forming membrane-bound vacuoles known as morulae that contain clusters of 1 to over 400 organisms. These exhibit a small, pleomorphic morphology, appearing as cocci or coccobacilli measuring 0.4–0.6 μm in diameter for dense-cored forms and up to 0.7–1.9 μm for reticulate cells, with morulae inclusions reaching 1.0–6.0 μm in width. Although classified as Gram-negative due to their cell wall structure, Ehrlichia are poorly stained by conventional Gram methods because they lack a layer and (LPS), features confirmed by electron microscopy and genomic analyses showing absence of genes for these components. Entry into host cells occurs via filopodia-mediated receptor , where outer membrane proteins facilitate attachment and rearrangement, allowing the to invade phagocytic cells like monocytes and granulocytes. Once internalized, Ehrlichia undergo binary fission within the , progressing from reticulate cells to dense-cored elementary bodies, and in late infection stages, the induce host cell rupture to release progeny for dissemination. This intracellular lifestyle is supported by the 's avoidance of lysosomal fusion, enabling protected replication. Key surface components include outer membrane proteins (OMPs) such as major surface protein 2 (MSP2) and the OMP-1 (or p28) family, comprising up to 22 paralogs in species like E. chaffeensis, which mediate adhesion to host receptors and contribute to immune evasion through antigenic variation. These proteins are integral to the bacterium's interaction with the host environment, enabling survival without a traditional . Biochemically, Ehrlichia lack flagella and are non-motile, testing negative for and activities, reflecting their dependence on host resources for energy and metabolism. They acquire host ATP through a type IV secretion system, which translocates effectors to manipulate host cell processes and sustain intracellular persistence.

Life Cycle and Transmission Mechanisms

Ehrlichia species exhibit a biphasic life cycle that alternates between intracellular replication in mammalian hosts and maintenance within ixodid ticks as vectors. In mammalian hosts, the cycle begins with the uptake of dense-core elementary bodies into host monocytes or granulocytes via , where they differentiate into reticulate bodies that replicate by binary fission within a membrane-bound , forming clusters known as morulae. These reticulate bodies then redifferentiate into infectious elementary bodies, which are released to infect new host cells, perpetuating the infection. In ticks, Ehrlichia bacteria are acquired during blood meals from infected hosts and persist through transstadial transmission, passing from larval to nymphal and adult stages without to eggs in most species, though limited has been observed in some contexts. The bacteria multiply in the tick's epithelial cells and migrate to the salivary glands, enabling inoculation into new hosts during subsequent feeding. Primary vectors include for E. chaffeensis, for E. canis, and for the E. muris-like agent, with transmission occurring via during tick attachment. Transmission to mammals requires prolonged tick attachment, typically at least 24 hours, allowing sufficient time for bacterial dissemination from the salivary glands, though experimental studies suggest a range of 24–36 hours for efficient infection. In nature, the cycle is maintained through reservoir hosts such as for E. chaffeensis and domestic dogs for E. canis, which harbor persistent infections that sustain infection rates. A 2025 study reported detection of E. chaffeensis DNA in a Haemaphysalis longicornis collected in , USA, in 2021, raising concerns about the invasive Asian longhorned tick's potential role in expanding transmission, particularly in areas overlapping with established vectors like A. americanum.

History and Classification

Discovery and Early Research

Heartwater, a devastating of ruminants in , was first recognized in the as a fatal condition affecting , sheep, and goats, often linked to heavy infestations but without a clear . Pioneering work by veterinary researchers like Thomas Hutcheon in the late 1800s described its clinical signs, including high fever, nervous symptoms, and , establishing it as a distinct infectious entity. In 1900, the tick-borne transmission of heartwater was confirmed through experiments by L. M. Lounsbury, who demonstrated that the tropical bont tick (Amblyomma hebraeum) served as the vector by successfully reproducing the disease in susceptible animals via tick infestation. Sir Arnold Theiler, South Africa's chief veterinary officer, advanced these findings in subsequent studies, including contributions to diagnosis in 1904. A major milestone occurred in 1910 when Theiler identified Anaplasma marginale as the causative agent of anaplasmosis, a related tick-borne rickettsial disease in cattle, marking the first description of a pathogen in what would become the Anaplasmataceae family. The causative agent of heartwater was visualized in 1925 by E. V. Cowdry, who demonstrated colonial masses of the in endothelial cells of infected tissues and within ticks, initially naming it ruminantium. In 1935, canine monocytic was first reported in by Donatien and Lestoquard in , describing the disease in dogs with symptoms of fever, anorexia, and , caused by intra-leukocytic rickettsiae transmitted by the brown dog tick (). Early studies extended to , where similar infections were noted in military dogs during the 1930s, highlighting the pathogen's distribution in tropical regions. The Ehrlichia was formally proposed in 1945 by S. D. Moshkovski to honor Paul Ehrlich's foundational work in and , encompassing these obligate intracellular . By 1945, Neitz and developed the "infection and treatment" immunization method for heartwater, involving controlled exposure to the pathogen followed by tetracycline administration (such as oxytetracycline) to attenuate the infection while inducing immunity, a technique that became a cornerstone for protection in endemic areas.

Taxonomic Developments

The genus Ehrlichia was formally established in 1945 by Moshkovski, who reclassified certain rickettsial agents, including the agent of canine ehrlichiosis described in 1935 by Donatien and Lestoquard as Ehrlichia canis, marking the initial species classification within the genus and highlighting its tick-borne nature. The heartwater agent, originally described as Rickettsia ruminantium by Cowdry in 1925, was renamed Cowdria ruminantium in 1947 by Moshkovski in honor of Cowdry and later reclassified as Ehrlichia ruminantium in 2001 by Dumler et al. based on phylogenetic analyses. This taxonomic shift reflected emerging understanding of these obligate intracellular bacteria's shared morphological and pathogenic traits, distinguishing them from other rickettsiae. Further refinements occurred in the , exemplified by the elevation of a platelet-associated agent of infectious cyclic thrombocytopenia in dogs to species status as Ehrlichia platys in 1983 by French and Harvey, based on serological and morphological . The advent of molecular techniques in the revolutionized identification, enabling PCR-based detection that confirmed Ehrlichia chaffeensis as a in 1991 through 16S rRNA gene sequencing from infected monocytes. Similarly, in 1992, Anderson et al. proposed Ehrlichia ewingii as the etiological agent of canine granulocytic ehrlichiosis, again using PCR amplification and sequencing of the 16S rRNA gene from experimentally infected dogs. These advancements underscored the genus's diversity and its zoonotic potential, shifting from purely morphological criteria to phylogenetic analyses. In 2001, Dumler et al. reorganized the order Rickettsiales, elevating the family Anaplasmataceae to encompass Ehrlichia alongside genera like Anaplasma, Neorickettsia, and Wolbachia, based on 16S rRNA and other gene sequence similarities, as well as shared ecological and biological features. This restructuring unified previously fragmented tribes (Ehrlichieae and Wolbachieae) and facilitated broader recognition of these pathogens' evolutionary relationships. Subsequent molecular discoveries included the identification in 2009 of an Ehrlichia muris-like agent (later designated E. muris eauclairensis) as a cause of human ehrlichiosis in the upper Midwest United States, confirmed via PCR detection in patient blood and ticks. Reflecting these molecular insights, the U.S. Centers for Disease Control and Prevention (CDC) revised the national surveillance case definition for in 2024, mandating molecular confirmation (e.g., PCR with species-specific sequencing) for precise identification of Ehrlichia spp., thereby distinguishing it from and improving epidemiological accuracy. This update emphasizes the role of genetic tools in resolving provisional statuses and enhancing public health responses to emerging variants.

Species Diversity

Accepted Species

The genus Ehrlichia comprises formally accepted that are obligate intracellular with pronounced host specificity, primarily infecting mammals via vectors, as validated by the List of Prokaryotic names with Standing in Nomenclature (LPSN) as of 2025. These exhibit varying degrees of zoonotic potential and are distinguished by their primary reservoirs, transmission cycles, and geographic distributions, reflecting adaptations to specific ecological niches. Ehrlichia canis, first described in 1935, serves as the of the and is the primary of dogs, with a global distribution wherever the brown dog tick is prevalent; it causes canine monocytic ehrlichiosis. Ehrlichia chaffeensis, validly published in 1992, infects both humans and dogs as principal hosts and is endemic to the , where it is transmitted by the lone star tick ; it is the etiologic agent of . Ehrlichia ewingii, described in 1993, primarily affects granulocytes in humans and dogs and is restricted to the , vectored by ; infections typically result in a milder form of granulocytic compared to other species. Ehrlichia muris, initially isolated in 1991 with the E. muris subsp. eauclairensis formally proposed in 2009, is mainly associated with rodents as reservoir hosts and occurs in parts of the and , transmitted by ticks; it has been linked to emerging cases of human . Ehrlichia ruminantium, reclassified in 2001 from its original description in 1925, targets ruminants such as and sheep and is distributed across and parts of the , vectored by ticks; it causes heartwater disease, which leads to high mortality in . Ehrlichia minasensis, validly published in 2016, primarily infects ruminants including and is endemic to , transmitted by the Rhipicephalus microplus; it has been associated with bovine . Ehrlichia japonica, validly published in 2022, was isolated from Ixodes ovatus ticks and rodents in Japan; it shows potential as an emerging pathogen capable of causing severe human ehrlichiosis.

Provisional and Candidatus Species

Provisional species of Ehrlichia represent taxa that have been described based on morphological or preliminary molecular evidence but lack complete validation under formal taxonomic rules, often due to challenges in cultivation or full genomic characterization. Another provisional species, E. ovina, was described in 1945 from ovine monocytes in Turkey, associated with infections in domestic ruminants across the Mediterranean region, but remains incompletely characterized without cultured isolates or full genomic data. Note that E. platys, formerly considered a provisional Ehrlichia species causing infectious cyclic thrombocytopenia in dogs, was reclassified as Anaplasma platys in 2001 based on phylogenetic analyses and is no longer part of the genus Ehrlichia. Candidatus species denote uncultured Ehrlichia taxa provisionally named under the International Code of Nomenclature for Prokaryotes, typically identified through molecular detection in vectors or reservoirs without formal description. Candidatus Ehrlichia shimanensis, proposed in 2006 from , was detected in wild (Cervus nippon) and Haemaphysalis longicornis ticks using 16S rRNA sequencing, exhibiting 96-97% similarity to E. chaffeensis and suggesting a wildlife reservoir role. Candidatus Ehrlichia walkeri, named in 2003 from Ixodes ricinus ticks removed from asymptomatic humans in , represents an early example of a potential zoonotic variant identified via PCR amplification of the 16S rRNA gene, with sequences clustering near E. ruminantium. In , Candidatus E. khabarensis was described in 2015 from small mammals like rodents and insectivores in the region, confirmed by ultrastructural analysis and multi-locus sequencing (16S rRNA, ), indicating transmission by ixodid ticks in Siberian ecosystems. Further Candidatus species underscore the global diversity of Ehrlichia in . Candidatus E. rustica, proposed in 2016 from ticks in (though sequences have been noted in European contexts like badgers), was identified in Rhipicephalus spp. via 16S rRNA and genes, with low similarity (under 93%) to validated and associations with reservoirs. Candidatus E. senegalensis, named in 2020 from , was detected in native such as Mastomys erythroleucus and soft ticks (Ornithodoros sonrai) using 16S rRNA sequencing, representing a novel lineage in African sahelian ecosystems without known pathogenicity. In , Candidatus E. erythraense emerged in 2023 from human febrile cases in the Dabie Mountains, identified through blood PCR and sequencing of 16S rRNA and other loci, marking it as a potential cause of ehrlichiosis with sequences distinct from E. chaffeensis (about 96% identity). Additionally, Candidatus E. ornithorhynchi, described in 2018 from Australia, infects platypuses (Ornithorhynchus anatinus) and their specific vector Ixodes ornithorhynchi ticks in and , detected via high-throughput sequencing of blood and tick , with no evident association but widespread prevalence. These provisional and Candidatus Ehrlichia taxa are predominantly identified through 16S rRNA gene sequencing, a standard molecular method for detecting unculturable intracellular in ticks and wildlife hosts like , deer, and monotremes, which serve as key reservoirs. A 2024 report from further illustrates evolving species boundaries, where E. canis—typically accepted—was confirmed in a via Haemaphysalis punctata , an atypical vector, using 16S rRNA phylogenetic analysis of and samples.

Genomics and Evolution

Genome Organization

The genomes of Ehrlichia species are characteristically small, ranging from approximately 1.0 to 1.5 megabase pairs (Mbp), reflecting their intracellular lifestyle and reductive . This genome reduction is accompanied by a high AT content of 70-75%, which contributes to a low GC bias typical of Anaplasmataceae. As a result of this reductive process, Ehrlichia exhibit extensive gene loss, including the absence of genes for synthesis and de novo purine biosynthesis, necessitating reliance on host cellular resources for these essential components. Such losses underscore the genus's to , with metabolic pathways severely truncated compared to free-living . Ehrlichia genomes consist of a single circular averaging around 1 Mbp in length, with no evidence of multiple chromosomes. Plasmids are absent across the . Prominent among the conserved genetic features are key gene families involved in host interaction and survival. The OMP-1/p28 multigene , encoding major outer proteins, is tandemly arrayed in multiple copies—up to 22 in E. chaffeensis—and plays a critical role in immune evasion and cellular adhesion. Additionally, the dsb system, comprising disulfide bond-forming proteins like DsbA homologs, supports the functionality of the type IV secretion system by aiding in the proper folding of secreted effectors essential for intracellular persistence. A substantial portion of Ehrlichia genomes comprises pseudogenes and repetitive elements, indicative of ongoing genome decay. In E. ruminantium, for instance, pseudogenes and repeats account for approximately 30-40% of the genome, with only 62% predicted to encode functional proteins. This high proportion of non-coding sequence highlights the dynamic instability and erosion characteristic of reductive evolution in obligate intracellular pathogens. Milestones in Ehrlichia genomics include the first complete genome sequence of E. ruminantium strain Welgevonden (1.516 Mbp) published in 2005, followed by those of E. canis strain Jake (1.315 Mbp) and E. chaffeensis strain Arkansas (1.176 Mbp) in 2006, which provided foundational insights into shared genomic architecture across the genus. These assemblies revealed the compact, syntenic nature of Ehrlichia chromosomes and facilitated comparative analyses of gene content. More recent sequencing efforts, such as the 2024 genome of E. canis strain YZ-1 (1.315 Mbp), continue to reveal conserved features amid strain variations.

Evolutionary Adaptations

Ehrlichia have evolved sophisticated genetic mechanisms to evade host immune responses and adapt to intracellular lifestyles, primarily through and fusion events that facilitate antigenic variation. In , the OMP-1 (outer membrane protein 1) locus contains a multigene family of up to 22 paralogous genes encoding immunodominant 28-kDa surface proteins, arising from tandem duplications that allow differential expression during infection to promote immune evasion. Similarly, in Ehrlichia ruminantium, multiple tandem repeats of variable copy number in intergenic regions enable phase variation, altering surface expression to enhance persistence in hosts. These duplications reflect an evolutionary strategy to generate diversity in surface epitopes without requiring extensive sequence changes, allowing Ehrlichia to persist in vectors and mammalian reservoirs. Recombination and positive selection further drive adaptation in Ehrlichia surface proteins, as evidenced by elevated nonsynonymous to ratios (dN/dS > 1) in key immunogenic loci. For instance, in E. canis, the gp36 (TRP36) gene exhibits positive selection at multiple codon sites (p ≤ 0.05), indicating immune-driven diversification of regions that facilitate host cell attachment and evasion. Complementing this, reductive has streamlined Ehrlichia genomes by eliminating genes for metabolic pathways such as biosynthesis and synthesis, fostering obligate dependence on host cells for nutrients and reducing the metabolic burden in nutrient-poor intracellular environments. This genome reduction, common across Rickettsiales, underscores an adaptation to parasitism, with over 300 hypothetical genes retained for host interaction but minimal evidence of beyond the order. Phylogenetic analyses place Ehrlichia within a monophyletic alongside in the family Anaplasmataceae, with E. ruminantium occupying a basal position characterized by elevated nucleotide substitution rates that contribute to strain diversity in African ruminants. In contrast, E. canis displays adaptations suited to canine and hosts, including sequence variability in immunoreactive proteins that likely arose through intragenomic recombination rather than plasmid involvement. Recent genomic studies highlight recombination as a key driver of zoonotic potential; for example, a 2023 analysis of a novel Ehrlichia in revealed recombination events in core genes that may have facilitated host jumps from rodents to humans, marking an emerging threat in .

Pathogenicity and Diseases

Mechanisms of Infection

Ehrlichia species initiate infection by adhering to and entering host cells, primarily monocytes, macrophages, and non-phagocytic cells such as endothelial cells. The process begins with bacterial surface proteins binding specific host receptors, inducing cytoskeletal rearrangements for uptake. In Ehrlichia chaffeensis, the outer membrane invasin EtpE binds the GPI-anchored receptor DNase X on the host cell surface, activating downstream signaling that promotes extension and facilitates bacterial internalization via an actin-dependent zipper mechanism. The protein TRP120, a surface-exposed adhesin on dense-core forms, further supports entry by interacting with diverse host proteins involved in signaling and cytoskeletal organization, enabling attachment to non-phagocytic cells. This coordinated adhesion and filopodia-mediated uptake allows Ehrlichia to invade without relying on classical phagocytic pathways. Upon entry, Ehrlichia resides within a specialized, membrane-bound known as the Ehrlichia-containing vacuole (ECV), which matures into morulae clusters to support replication while evading lysosomal fusion. The bacterium inhibits host cell through effectors like Ank200, a nucleomodulin translocated via the type I secretion system (T1SS) that binds GC-rich motifs in host DNA to upregulate anti-apoptotic genes such as and downregulate pro-apoptotic factors like BAX. Morulae formation further protects against degradation by excluding lysosomal markers like LAMP1, while Ehrlichia scavenges essential nutrients from the host, including acquired from plasma membranes and endocytic pathways to enrich its own membranes and support proliferation. Ehrlichia modulates the host immune response to promote persistence, notably by downregulating expression on infected macrophages, thereby impairing to T cells. The type IV secretion system (T4SS) plays a central role in this evasion by injecting effectors such as Etf-1, which localizes to mitochondria to block and induces by recruiting RAB5 and the Beclin-1/VPS34 complex, capturing host nutrients while suppressing neutrophil-mediated responses through delayed and reduced inflammatory signaling. Other T4SS substrates, like the Ehrlichia immunodominant (EIGP), contribute to immune subversion by altering production and host signaling pathways. Infection concludes with bacterial exit via host cell or non-lytic , releasing infectious dense-core forms that disseminate to new cells. This release occurs after 48–72 hours of replication.

Diseases in Humans

(HME), caused by , is the most common form of in humans, primarily transmitted by the lone star tick () in the United States. Symptoms typically emerge after an of 5–14 days and include fever, , , , and , with gastrointestinal involvement such as or vomiting in about one-third of cases. occurs in up to 60% of children but fewer than 30% of adults, often presenting as a maculopapular or petechial eruption that may involve the trunk and extremities. The disease is generally mild to moderate but can progress to severe complications in immunocompromised individuals, including , (ARDS), renal failure, and . National surveillance data indicate a hospitalization rate of approximately 57% and a case-fatality rate of 1%, with higher mortality (up to 4%) in those with delayed or underlying conditions. Human ewingii ehrlichiosis, caused by E. ewingii, primarily infects neutrophils and is also vectored by the lone star tick, predominantly in the southern and . It shares many nonspecific symptoms with HME, such as fever, , and , but tends to be milder overall, with fewer gastrointestinal complaints. Rash is infrequent, reported in less than 30% of cases, and severe outcomes like organ failure are rare, though and are common laboratory findings. This form is often underdiagnosed due to its subtlety but responds well to early therapy. Emerging Ehrlichia species have been implicated in human infections, expanding the spectrum of disease. E. muris eauclairensis, first identified in human cases from the Midwest in 2009, causes symptoms similar to HME, including fever, , and elevated liver enzymes, but is typically less severe with infrequent ; cases have been reported annually in states like and since its discovery. In August 2023, a confirmed human with E. canis—primarily a canine pathogen—was reported in , involving fever and confirmed by PCR from blood and an attached Haemaphysalis punctata , highlighting potential zoonotic spillover. Additionally, in 2023, an outbreak in and provinces of China involved 19 confirmed human cases of due to Candidatus Ehrlichia erythraense, presenting with fever and , marking the emergence of this novel -borne agent. does not spread person-to-person, emphasizing the role of vectors in transmission.

Diseases in Animals

Canine monocytic ehrlichiosis, caused by Ehrlichia canis, is a tick-borne disease primarily affecting dogs worldwide, transmitted by the brown dog tick (Rhipicephalus sanguineus). The disease progresses through three phases: an acute phase occurring 2-4 weeks post-infection, characterized by fever, anorexia, lymphadenopathy, and thrombocytopenia leading to bleeding tendencies such as epistaxis and petechiae; a subclinical phase where infected dogs appear clinically normal but harbor the bacteria; and a chronic phase marked by severe immunosuppression, bone marrow hypoplasia, recurrent fever, weight loss, and potentially fatal hemorrhaging. This disease imposes significant economic burdens on veterinary care, particularly for working and military dogs, with global distribution tied to the vector's range in tropical and subtropical regions. Heartwater, induced by Ehrlichia ruminantium, is a severe tick-borne rickettsial affecting ruminants, predominantly in and parts of the , vectored by ticks. Clinical manifestations include high fever, anorexia, listlessness, respiratory distress, and neurological signs such as tremors, incoordination, and convulsions, often culminating in hydropericardium, , and death. Mortality rates in susceptible can reach 30-90%, with lower rates in endemic areas due to partial immunity, but the disease causes substantial economic losses estimated at R1.3 billion (approximately US$87 million) annually in (as of 2022), driven by mortality, reduced milk production, treatment costs, and extensive use. Ecologically, it hinders improvement programs and limits the introduction of high-yielding breeds into affected regions. Equine granulocytic anaplasmosis, historically attributed to Ehrlichia equi but now classified under , causes fever, lethargy, , and in horses, with economic implications for equine industries through reduced performance and veterinary interventions. In sheep, provisional species Ehrlichia ovina is associated with tropical , presenting with fever, , , and high mortality in small ruminants, though its taxonomic status remains incompletely defined and primarily reported in regions like and . These infections underscore the evolving classification within the Anaplasmataceae family and their impacts on productivity. Wildlife species, including (Odocoileus virginianus) and various , serve as key reservoirs for Ehrlichia species, often maintaining subclinical infections that facilitate enzootic cycles without overt disease. For instance, are the primary reservoir for E. chaffeensis, supporting tick populations and enabling zoonotic spillover to humans through shared vectors like the lone star tick (), which amplifies ecological risks in overlapping habitats. These reservoir dynamics contribute to the persistence of Ehrlichia in ecosystems, posing indirect economic threats to agriculture and via vector amplification.

Epidemiology

Global Distribution and Incidence

Ehrlichiosis, primarily caused by , is most prevalent , where more than 2,000 cases are reported annually, with the majority attributed to this . The incidence rate for E. chaffeensis infections stands at approximately 3.2 cases per million person-years in the Southeast, where the disease is endemic due to the widespread presence of the lone star tick (), the primary vector. In 2024, the CDC updated the case definition for ehrlichiosis to require molecular identification of specific Ehrlichia , potentially refining future surveillance. Cases are rising in the Northeast, driven by the expansion of tick populations, including the invasive Asian longhorned tick (Haemaphysalis longicornis), which has been found carrying E. chaffeensis in states like . By 2025, this tick has established populations in over 20 U.S. states, contributing to broader geographic spread. In , human ehrlichiosis remains rare, though emerging cases highlight growing risks. A confirmed human with Ehrlichia canis was reported in in August 2023, linked to a Haemaphysalis punctata tick bite, marking one of the first documented instances in the region. Overall human incidence is low, but E. canis is increasingly detected in dogs across , suggesting potential for zoonotic spillover. In and , Ehrlichia ruminantium is endemic, particularly in , where it causes heartwater in ruminants with high mortality rates up to 90% in susceptible . Seropositivity rates in African cattle range from 20% to 50%, indicating widespread exposure, though underreporting of human cases is common in tropical regions due to limited surveillance. In , E. canis predominates in canine populations, with cases sporadic; a 2023 study in identified a novel Candidatus Ehrlichia species associated with febrile illnesses in the and provinces, underscoring emerging threats. Globally, ehrlichiosis cases are increasing, influenced by climate change and tick range expansion, which facilitate pathogen dissemination into new areas. For instance, in , 28 cases were reported from 2019 to 2023, reflecting broader U.S. trends of rising incidence. Underreporting persists in tropical and subtropical zones, where animal reservoirs maintain high pathogen circulation.

Risk Factors and Vectors

Transmission of Ehrlichia species primarily occurs through bites from infected ticks, with Amblyomma americanum (lone star tick) serving as the main vector for E. chaffeensis in the eastern and south-central United States. Rhipicephalus sanguineus (brown dog tick) is the principal vector for E. canis worldwide, particularly in canine populations. The invasive Haemaphysalis longicornis (Asian longhorned tick), which has spread across the eastern U.S. by 2025, has been found carrying E. chaffeensis DNA, raising concerns for expanded transmission risks. Human exposure to Ehrlichia is heightened among outdoor workers, such as landscapers and hikers, due to increased contact in endemic areas. Elderly individuals and those who are immunocompromised face greater risks of severe infection following exposure. Transmission peaks seasonally from May to July, aligning with heightened activity and in warmer months. Climate warming contributes to the northward expansion of tick vectors, including species that facilitate co-infections with pathogens like , which can exacerbate Ehrlichia disease severity. Such environmental shifts broaden suitable habitats for ticks, increasing overall transmission potential in previously unaffected regions. In animals, in endemic tropical and subtropical areas are vulnerable to Ehrlichia species transmitted by regional ticks, leading to economic impacts on . For E. canis, international travel poses a significant risk, as infected dogs can introduce the pathogen to new tick populations and naive hosts. Prevention efforts are hampered by low public awareness of Ehrlichia risks outside the , particularly in regions like where diagnostic challenges and underreporting persist.

Diagnosis and Management

Diagnostic Techniques

Diagnosis of Ehrlichia infections relies on a combination of methods, including , , and molecular techniques, to detect the presence of the bacterium or in patients presenting with compatible clinical symptoms such as fever, , and . These approaches are essential due to the nonspecific nature of symptoms, which overlap with other tick-borne diseases. Microscopic examination of Giemsa-stained peripheral smears can reveal intraleukocytic morulae, characteristic inclusions of within monocytes (for E. chaffeensis) or granulocytes (for E. ewingii), typically during the first week of illness. However, this method has low sensitivity, approximately 10%, and is not reliable for species differentiation, making it unsuitable as a standalone diagnostic tool. Serologic testing using the indirect fluorescent antibody (IFA) assay for immunoglobulin G (IgG) antibodies serves as the reference standard for confirming Ehrlichia infections. A four-fold increase in titer between acute (within the first two weeks of illness) and convalescent (2-10 weeks later) paired sera, or a single convalescent titer of ≥1:128, indicates infection. Cross-reactivity with Anaplasma species is common, necessitating side-by-side IFA testing in endemic areas for accurate interpretation. IgM testing is unreliable due to frequent false positives. Molecular methods, particularly (PCR), provide direct detection of Ehrlichia DNA in , tissue, or and are most sensitive during the acute phase before antibiotic initiation. Common targets include the 16S rRNA gene for broad detection, as well as dsb and genes for species-specific identification. Quantitative real-time PCR (qPCR) enhances sensitivity and allows for bacterial load quantification, with high sensitivity in early when performed appropriately. A positive PCR result confirms active , though a negative result does not exclude it, especially post-treatment. According to 2024 CDC guidelines, molecular confirmation via PCR is required for species-specific diagnosis of infections due to serologic limitations. Key challenges include early seronegativity, where up to 85% of patients test negative in the first week, underscoring the need for paired sera and empiric treatment based on clinical suspicion.

Treatment and Prevention

The primary treatment for ehrlichiosis involves antimicrobial therapy with as the first-line agent, recommended for patients of all ages including children and pregnant individuals when the benefits outweigh potential risks. For adults and children weighing 45 kg or more, the standard regimen is 100 mg orally or intravenously twice daily, continued for at least 5-7 days or until the patient has been afebrile for 72 hours with clinical improvement. For children under 45 kg, the dose is 2.2 mg/kg body weight twice daily (maximum 100 mg per dose). Early initiation of , ideally within the first week of illness, typically resolves fever within 24-48 hours and prevents severe complications. In cases where doxycycline is contraindicated, alternatives such as (for children) or rifampin (particularly in ) may be considered, though evidence is limited and consultation with an infectious specialist is advised; typical durations for these agents range from 7-14 days based on clinical response. Supportive care is essential for severe infections, which may require hospitalization; measures include intravenous fluids for hydration, blood transfusions for or , and close monitoring for complications such as renal failure, , or . Prevention of ehrlichiosis focuses on tick bite avoidance and , as no human is available as of 2025. Key strategies include applying repellents containing (20-30% concentration) to skin and to clothing, wearing long sleeves and pants tucked into socks in endemic areas, and performing thorough tick checks after outdoor activities with prompt removal using fine-tipped tweezers within 24 hours to minimize transmission risk. Antibiotic prophylaxis after tick bites is not recommended. efforts emphasize community education on tick habits, landscape management to reduce tick habitats (e.g., clearing brush and mowing lawns), and including acaricides for high-risk areas. For animals, particularly dogs susceptible to E. canis, year-round tick preventives such as collars, topicals, or oral medications are advised, though no commercial exists for canine ehrlichiosis. With prompt treatment, over 90% of patients achieve full recovery, and the overall is approximately 1-3%, though delays in or underlying comorbidities can increase mortality to 10% or higher in severe cases.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK441966/
  2. https://www.cdc.gov/ehrlichiosis/about/index.html
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3767467/
  4. https://doi.org/10.1017/S1462399410001730
  5. https://doi.org/10.1016/j.micinf.2015.11.001
  6. https://doi.org/10.1016/j.mib.2009.12.008
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC5606584/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC9863373/
  9. https://pubmed.ncbi.nlm.nih.gov/9593039/
  10. https://wwwnc.cdc.gov/eid/article/31/6/25-0034_article
  11. https://journals.jsava.aosis.co.za/index.php/jsava/article/download/208/190
  12. https://www.cabidigitallibrary.org/doi/full/10.1079/cabicompendium.87241
  13. http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0030-24652009000100017
  14. https://pubmed.ncbi.nlm.nih.gov/19967931/
  15. https://pubmed.ncbi.nlm.nih.gov/26601456/
  16. https://microbewiki.kenyon.edu/index.php/Ehrlichia:_tick-borne_pathogen_in_canines_and_humans
  17. https://lpsn.dsmz.de/genus/ehrlichia
  18. https://www.researchgate.net/publication/269728367_A_user-friendly_and_scalable_process_to_prepare_a_ready-to-use_inactivated_vaccine_The_example_of_heartwater_in_ruminants_under_tropical_conditions
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC3053144/
  20. https://doi.org/10.1099/00207713-51-6-2145
  21. https://avmajournals.avma.org/view/journals/ajvr/44/12/ajvr.1983.44.12.2407.xml
  22. https://journals.asm.org/doi/10.1128/jcm.29.12.2838-2842.1991
  23. https://www.microbiologyresearch.org/content/journal/ijsem/10.1099/00207713-42-2-299
  24. https://pubmed.ncbi.nlm.nih.gov/11760958/
  25. https://wwwnc.cdc.gov/eid/article/24/6/17-1755_article
  26. https://wwwnc.cdc.gov/eid/article/31/2/24-0279_article
  27. https://lpsn.dsmz.de/species/ehrlichia-canis
  28. https://doi.org/10.1099/00207713-30-1-225
  29. https://lpsn.dsmz.de/species/ehrlichia-chaffeensis
  30. https://lpsn.dsmz.de/species/ehrlichia-muris
  31. https://doi.org/10.1099/00207713-45-2-250
  32. https://lpsn.dsmz.de/species/ehrlichia-ruminantium
  33. https://lpsn.dsmz.de/species/ehrlichia-minasensis
  34. https://doi.org/10.1099/ijsem.0.000895
  35. https://lpsn.dsmz.de/species/ehrlichia-japonica
  36. https://doi.org/10.1186/s12864-020-07309-z
  37. https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-019-3742-y
  38. https://lpsn.dsmz.de/species/anaplasma-platys
  39. https://doi.org/10.1099/00207713-51-2-365
  40. https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=179101
  41. https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1749-6632.2003.tb07352.x
  42. https://pubmed.ncbi.nlm.nih.gov/26096852/
  43. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004367
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC10218615/
  45. https://www.ijidonline.com/article/S1201-9712(23)00118-2/fulltext
  46. https://pubmed.ncbi.nlm.nih.gov/29284563/
  47. https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-022-05600-4
  48. https://wwwnc.cdc.gov/eid/article/30/12/24-0339_article
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC1482910/
  50. https://pubmed.ncbi.nlm.nih.gov/38257951/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC7789307/
  52. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.830180/full
  53. https://genome.jgi.doe.gov/portal/ehrca/ehrca.home.html
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC128143/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC127935/
  56. https://www.pnas.org/doi/10.1073/pnas.0406633102
  57. https://journals.asm.org/doi/10.1128/jb.188.7.2533-2542.2006
  58. https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.0020021
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC6863331/
  60. https://bmcecolevol.biomedcentral.com/articles/10.1186/1471-2148-12-243
  61. https://pubmed.ncbi.nlm.nih.gov/36967037/
  62. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003666
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC8546699/
  64. https://www.annualreviews.org/doi/10.1146/annurev-micro-091014-104411
  65. https://pubmed.ncbi.nlm.nih.gov/14592737/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC5103349/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC3004962/
  68. https://www.cdc.gov/ehrlichiosis/signs-symptoms/index.html
  69. https://www.cdc.gov/ehrlichiosis/hcp/clinical-signs/index.html
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC11324158/
  71. https://wwwnc.cdc.gov/eid/article/22/5/15-2009_article
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC2882064/
  73. https://www.dhs.wisconsin.gov/tick/ehrlichiosis-data.htm
  74. https://www.cfsph.iastate.edu/Factsheets/pdfs/ehrlichiosis.pdf
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC85367/
  76. https://www.cfsph.iastate.edu/Factsheets/pdfs/heartwater.pdf
  77. https://pubmed.ncbi.nlm.nih.gov/35367935/
  78. https://edis.ifas.ufl.edu/publication/IN1327
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC3453519/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC9940300/
  81. https://wwwnc.cdc.gov/eid/article/10/12/04-0707_article
  82. https://my.clevelandclinic.org/health/diseases/17958-ehrlichiosis
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC4710445/
  84. https://www.cdc.gov/ehrlichiosis/data-research/facts-stats/index.html
  85. https://www.newsweek.com/asian-longhorned-tick-found-maine-map-2127290
  86. https://pubmed.ncbi.nlm.nih.gov/39592414/
  87. https://www.mdpi.com/2076-0817/13/12/1119
  88. https://www.merckvetmanual.com/generalized-conditions/heartwater/heartwater
  89. http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S1019-91282008000200004
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC6587693/
  91. https://portal.ct.gov/dph/epidemiology-and-emerging-infections/ehrlichiosis
  92. https://www.sciencedirect.com/science/article/abs/pii/S037811351400217X
  93. https://stacks.cdc.gov/view/cdc/151749/cdc_151749_DS1.pdf
  94. https://www.researchgate.net/publication/339390833_Increased_Incidence_of_Ehrlichia_chaffeensis_Infections_in_the_United_States_2012_Through_2016
  95. https://royalsocietypublishing.org/doi/10.1098/rstb.2014.0051
  96. https://www.merckvetmanual.com/integumentary-system/ticks/ixodid-ticks
  97. https://www.business.qld.gov.au/industries/service-industries-professionals/service-industries/veterinary-surgeons/ehrlichia-canis
  98. https://wwwnc.cdc.gov/eid/article/31/9/25-0479_article
  99. https://www.cdc.gov/ehrlichiosis/hcp/diagnosis-testing/index.html
  100. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540185/all/Ehrlichia_species
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC2815638/
  102. https://www.cdc.gov/ehrlichiosis/hcp/clinical-care/index.html
  103. https://emedicine.medscape.com/article/235839-treatment
  104. https://emedicine.medscape.com/article/235839-overview
Add your contribution
Related Hubs
User Avatar
No comments yet.